221 related articles for article (PubMed ID: 14634209)
1. Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.
Bliskovsky V; Ramsay ES; Scott J; DuBois W; Shi W; Zhang S; Qian X; Lowy DR; Mock BA
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):14982-7. PubMed ID: 14634209
[TBL] [Abstract][Full Text] [Related]
2. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.
Zhang SL; DuBois W; Ramsay ES; Bliskovski V; Morse HC; Taddesse-Heath L; Vass WC; DePinho RA; Mock BA
Mol Cell Biol; 2001 Jan; 21(1):310-8. PubMed ID: 11113205
[TBL] [Abstract][Full Text] [Related]
3. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
Zhang S; Ramsay ES; Mock BA
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2429-34. PubMed ID: 9482902
[TBL] [Abstract][Full Text] [Related]
4. The plasmacytoma resistance gene, Pctr2, delays the onset of tumorigenesis and resides in the telomeric region of chromosome 4.
Mock BA; Hartley J; Le Tissier P; Wax JS; Potter M
Blood; 1997 Nov; 90(10):4092-8. PubMed ID: 9354679
[TBL] [Abstract][Full Text] [Related]
5. Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice.
Potter M; Mushinski EB; Wax JS; Hartley J; Mock BA
Cancer Res; 1994 Feb; 54(4):969-75. PubMed ID: 8313388
[TBL] [Abstract][Full Text] [Related]
6. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions.
Peterson RT; Beal PA; Comb MJ; Schreiber SL
J Biol Chem; 2000 Mar; 275(10):7416-23. PubMed ID: 10702316
[TBL] [Abstract][Full Text] [Related]
7. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression.
Vilella-Bach M; Nuzzi P; Fang Y; Chen J
J Biol Chem; 1999 Feb; 274(7):4266-72. PubMed ID: 9933627
[TBL] [Abstract][Full Text] [Related]
8. p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB.
Zhang S; Qian X; Redman C; Bliskovski V; Ramsay ES; Lowy DR; Mock BA
Oncogene; 2003 Apr; 22(15):2285-95. PubMed ID: 12700664
[TBL] [Abstract][Full Text] [Related]
9. The transcription factor MZF1 differentially regulates murine
Zhang S; Shi W; Ramsay ES; Bliskovsky V; Eiden AM; Connors D; Steinsaltz M; DuBois W; Mock BA
J Biol Chem; 2019 Nov; 294(45):16756-16764. PubMed ID: 31548308
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.
Liu X; Powlas J; Shi Y; Oleksijew AX; Shoemaker AR; De Jong R; Oltersdorf T; Giranda VL; Luo Y
Anticancer Res; 2004; 24(5A):2697-704. PubMed ID: 15517874
[TBL] [Abstract][Full Text] [Related]
11. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein.
Peterson RT; Desai BN; Hardwick JS; Schreiber SL
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4438-42. PubMed ID: 10200280
[TBL] [Abstract][Full Text] [Related]
12. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
Sabers CJ; Martin MM; Brunn GJ; Williams JM; Dumont FJ; Wiederrecht G; Abraham RT
J Biol Chem; 1995 Jan; 270(2):815-22. PubMed ID: 7822316
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface.
Luengo JI; Yamashita DS; Dunnington D; Beck AK; Rozamus LW; Yen HK; Bossard MJ; Levy MA; Hand A; Newman-Tarr T
Chem Biol; 1995 Jul; 2(7):471-81. PubMed ID: 9383449
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the transforming activity of a truncated Int6 gene, in vitro.
Rasmussen SB; Kordon E; Callahan R; Smith GH
Oncogene; 2001 Aug; 20(38):5291-301. PubMed ID: 11536042
[TBL] [Abstract][Full Text] [Related]
15. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Hosoi H; Dilling MB; Shikata T; Liu LN; Shu L; Ashmun RA; Germain GS; Abraham RT; Houghton PJ
Cancer Res; 1999 Feb; 59(4):886-94. PubMed ID: 10029080
[TBL] [Abstract][Full Text] [Related]
17. Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis.
Mock BA; Krall MM; Dosik JK
Proc Natl Acad Sci U S A; 1993 Oct; 90(20):9499-503. PubMed ID: 8105477
[TBL] [Abstract][Full Text] [Related]
18. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
Cafferkey R; Young PR; McLaughlin MM; Bergsma DJ; Koltin Y; Sathe GM; Faucette L; Eng WK; Johnson RK; Livi GP
Mol Cell Biol; 1993 Oct; 13(10):6012-23. PubMed ID: 8413204
[TBL] [Abstract][Full Text] [Related]
19. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
20. The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase.
Choi JH; Bertram PG; Drenan R; Carvalho J; Zhou HH; Zheng XF
EMBO Rep; 2002 Oct; 3(10):988-94. PubMed ID: 12231510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
